×
About 463 results

ALLMedicine™ Cold Agglutinin Disease Center

Research & Reviews  151 results

An Open-label Study of ALPN-303 in Subjects With Autoimmune Cytopenias
https://clinicaltrials.gov/ct2/show/NCT05757570

Mar 7th, 2023 - The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially b...

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
https://clinicaltrials.gov/ct2/show/NCT05086744

Feb 13th, 2023 - The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

Spurious macrocytic anaemia in a patient with systemic lupus erythematosus: cold agglut...
https://doi.org/10.1007/s10067-023-06536-5
Clinical Rheumatology; Nagahata K, Suzuki C et. al.

Feb 9th, 2023 - Spurious macrocytic anaemia in a patient with systemic lupus erythematosus: cold agglutinin disease.|2023|Nagahata K,Suzuki C,Takahashi H,|

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088
https://clinicaltrials.gov/ct2/show/NCT04802057

Jan 23rd, 2023 - The screening period for this study is up to 6 weeks. The treatment period for this study will continue until SAR445088 is approved in the respective country, or until SAR445088 development is discontinued, whichever comes first.

Daratumumab as a novel treatment option in refractory ITP.
https://doi.org/10.1016/j.bcmd.2023.102724
Blood Cells, Molecules & Diseases; Vernava I, Schmitt CA

Jan 21st, 2023 - Primary immune thrombocytopenia (ITP) in adult patients typically presents as a repeatedly relapsing disease in need of multiple lines of therapy. Here we report the clinical courses of two patients, an 82-year-old female and a 54-year-old male, w...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  15 results

An Open-label Study of ALPN-303 in Subjects With Autoimmune Cytopenias
https://clinicaltrials.gov/ct2/show/NCT05757570

Mar 7th, 2023 - The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially b...

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
https://clinicaltrials.gov/ct2/show/NCT05086744

Feb 13th, 2023 - The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088
https://clinicaltrials.gov/ct2/show/NCT04802057

Jan 23rd, 2023 - The screening period for this study is up to 6 weeks. The treatment period for this study will continue until SAR445088 is approved in the respective country, or until SAR445088 development is discontinued, whichever comes first.

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
https://clinicaltrials.gov/ct2/show/NCT05132127

Dec 15th, 2022 - The period between screening/baseline visit (upon the participant's completion* of the CARDINAL and CADENZA studies) and end of treatment with sutimlimab in this study is determined by sutimlimab or other appropriate CAD therapy becoming commercia...

see more →

News  17 results

Cracking the “MGUS” Code Reveals Monoclonal Gammopathy of Clinical Significance:
https://www.onclive.com/view/cracking-the-mgus-code-reveals-monoclonal-gammopathy-of-clinical-significance-

Nov 1st, 2022 - When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment. On initial patient consultation, gathering a detailed patient history and thorough physical exam can catch clinically signifi...

Novel Treatment Strategies in Immune Thrombocytopenia: Complement Inhibitors
https://www.onclive.com/view/novel-treatment-strategies-in-immune-thrombocytopenia-complement-inhibitors

Oct 11th, 2022 - Transcript: Morey Blinder, MD: Let’s talk about just some of these other therapies. How about sutimlimab, which I think is available now for cold agglutinin disease, if I’m not mistaken as marketed as Enjaymo. Any thoughts about that as an ITP [im...

Experimental Agents for ITP
https://www.onclive.com/view/experimental-agents-for-itp

Feb 23rd, 2022 - Craig Kessler, MD: Sutimlimab is a humanized monoclonal antibody that selectively inhibits activation of the complement pathway by binding to complement 1S. This drug, which is not approved, will be marketed by Sanofi. It was originally developed ...

Old Drug, New Cancer Tricks? No Need to Delay Mammo; 'CeMe' Cervical Cancer Campaign
https://www.medpagetoday.com/hematologyoncology/othercancers/97125

Feb 10th, 2022 - A 30-year-old investigational drug could get another look as a potential cancer therapy as a result of the growing emphasis on precision medicine. (VCU Health, Molecular Cancer Therapeutics) The Centers for Medicare & Medicaid Services expanded el...

U.S. COVID Death Toll Tops 900K; More Large Waves Ahead? Monkeys, Bats, Rats, Oh My!
https://www.medpagetoday.com/infectiousdisease/covid19/97046

Feb 7th, 2022 - Note that some links may require registration or subscription. As of Monday at 8 a.m. ET, the unofficial U.S. COVID toll is 76,505,941 cases and 902,626 deaths, up 2,172,413 and 18,361 respectively, versus a week ago. An NIH primate study appears ...

see more →

Patient Education  1 results see all →